Influenza A virus continues to present a major public health challenge because of rapid viral evolution and emerging resistance to current antivirals. The authors evaluated whether manganese ions could exert a direct antiviral effect against influenza A. Prior work has shown manganese can modulate host antiviral immunity, but its direct impact on influenza virus replication had not been clearly defined.
Using cultured-cell infection systems, the study reports that manganese chloride (MnCl2) potently inhibited replication of both H1N1 and H3N2 influenza A subtypes. Activity was observed at micromolar concentrations according to the abstract. The antiviral effect was documented in cell culture assays measuring viral replication, although specific assay formats, cell lines, and exact concentration–response data are not detailed in the abstract.
The antiviral activity described was specific to Mn2+. The authors tested several other divalent cations—calcium (Ca2+), copper (Cu2+), zinc (Zn2+), and magnesium (Mg2+)—and found that these did not share the antiviral effect seen with MnCl2. This specificity supports a distinct biochemical interaction between Mn2+ and viral components rather than a nonspecific ionic effect.
Time-of-addition experiments and molecular analyses indicated that MnCl2 primarily affects post-entry stages of the viral lifecycle. The compound suppressed synthesis of viral mRNA, consistent with interference in viral transcription or early replication steps after the virus has entered host cells. Details on the timing, experimental design, or quantitative reduction of viral mRNA were not provided in the abstract.
Biochemical assays reported in the study showed that MnCl2 directly inhibited the RNA cleavage activity of the viral PA endonuclease. The PA subunit of influenza virus polymerase mediates endonucleolytic cleavage of host capped RNAs (cap-snatching), a required step for viral mRNA transcription. Inhibition of PA endonuclease activity by Mn2+ provides a plausible molecular mechanism for the observed suppression of viral mRNA synthesis and replication.
To further interrogate the target, the investigators used pharmacological antagonism with the approved PA endonuclease inhibitor baloxavir. The observed antagonism between MnCl2 and baloxavir in the reported experiments supports the conclusion that PA endonuclease is a key functional target of Mn2+ antiviral action. The abstract does not provide experimental details about the antagonism assays or dose combinations.
The study extended findings to an in vivo mouse model. Intranasal administration of MnCl2 mitigated influenza-associated body weight loss, reduced mortality, and decreased pulmonary viral RNA loads. These outcomes indicate that MnCl2 exhibited protective antiviral effects in animals when delivered to the respiratory tract. The abstract does not report treatment timing, dosing regimen, safety or toxicity assessments, or statistical measures.
Collectively, the data presented in the abstract identify Mn2+ as a direct inhibitor of influenza A virus replication that acts, at least in part, by targeting the PA endonuclease. The findings provide a conceptual basis for exploring metal ion–based antiviral strategies against influenza A. Important limitations based on the source abstract include the preprint status (not peer reviewed) and the absence of detailed methods, dosing, toxicity, and comprehensive efficacy metrics in the abstract. Further peer-reviewed studies will be needed to confirm these results, define therapeutic windows, and characterize safety before clinical translation.
Note: This summary is derived from the preprint abstract. Specific experimental protocols, quantitative results, and full data are not reported in the abstract and were not invented here.